The substantial dilutive raise at a discount gives the company cash into H2 2028 but weighs on near-term valuation. Watch for the efficacy of TSHA-102 clinical data as the primary catalyst, cash runway is now a non-factor for at least 18 months. The greenshoe exercise in the next 30 days will indicate underwriter demand. Monitor for any corresponding insider lock-up expiration disclosures.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $6.34entry
- T+1 · 5mo ago +6.15%α +4.50% · $6.73
- T+5 · 4mo ago +3.00%α +0.83% · $6.53
- T+20 · 4mo ago −8.04%α −9.30% · $5.83
- T+60 · 8w ago −20.50%α −26.61% · $5.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant, alongside a 30-day underwriter option for up to 5,000,000 additional shares. The offering, closed simultaneously with this 8-K, was executed at a 13.5% discount to the prior day's close of $6.94, raising ~$187.4M in net proceeds (or ~$215.6M if the greenshoe is fully exercised). The company states these funds extend its cash runway into H2 2028. The dilutive transaction offsets the capital-extending benefit, making the net effect neutral with a modest negative bias from the discount.
Key Financial Metrics
Key Facts
- Priced 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant
- Public offering price of $6.00 represents a ~13.5% discount to prior close of $6.94
- Gross proceeds of ~$200.0M; estimated net proceeds of ~$187.4M (or ~$215.6M if greenshoe fully exercised)
- Underwriters granted 30-day option to purchase up to 5,000,000 additional shares
- Closing expected June 26, 2026; proceeds to fund operations into H2 2028
- Offering issued under existing S-3ASR shelf registration (File No. 333-291244), filed Nov 4, 2025
- Pre-funded warrants have a $0.001 exercise price and are exercisable immediately until exercised in full
Financial Impact
The company raised ~$187.4M net from the offering. Based on 32.5M new shares issued versus prior outstanding (not specified), the dilution is significant, likely 50–100%+ increase in share count for a ~$2.0B market cap biotech. The ~13.5% discount to market is substantial for a non-distressed follow-on.
Risk Factors
- Dilution from the offering is substantial, affecting EPS and per-share valuation even if cash runway is extended
- At-the-market discount of ~13.5% may signal weak demand or urgency, pressuring the stock near term
- Clinical-stage biotech with no approved products; reliance on TSHA-102 data for value creation
- Underwriters' decision on greenshoe option (up to 5M additional shares) will reflect real-time demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-282855 |
| Document: d121397dex41.htm | 0001193125-26-282855 |
| Document: d121397d8k.htm | 0001193125-26-282855 |
| Document: d121397dex51.htm | 0001193125-26-282855 |
| Document: d121397dex992.htm | 0001193125-26-282855 |
| Document: d121397dex991.htm | 0001193125-26-282855 |
| Document: 0001193125-26-282855-index-headers.html | 0001193125-26-282855 |
| Document: 0001193125-26-282855-index.html | 0001193125-26-282855 |
| Document: 0001193125-26-282855.txt | 0001193125-26-282855 |
Track record
14 reports on TSHA
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Viewing Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers